Which three medications are first-line therapy for hepatitis B?

Which three medications are first-line therapy for hepatitis B?

• A. Pegylated interferon, entecavir, and tenofovir
• B. Interferon, lamivudine, adefovir
• C. Sofosbuvir, ledipasvir, ribavirin
• D. Zidovudine, lamivudine, abacavir

Answer: (A)

In chronic hepatitis B, therapy aims to rapidly suppress viral replication with regimens that remain effective over the long term and have low resistance. The best first-line options reflect a balance between immune-modulating therapy and potent antiviral agents. Pegylated interferon provides a finite, immune-based treatment course and can lead to durable responses or even HBsAg loss in some patients, making it an attractive option for those who can tolerate its side effects and who prefer a finite duration of therapy. However, its use is limited by contraindications and tolerability in many patients, such as those with advanced liver disease or autoimmune conditions. The other two first-line choices are nucleos(t)ide analogues, entecavir and tenofovir. These drugs are highly potent at suppressing HBV DNA, have a high barrier to resistance (especially important for long-term therapy), and are effective in a wide range of patients, including those with cirrhosis. Because they’re taken orally and typically require long-term, potentially lifelong treatment to maintain suppression, their strong resistance profile makes them reliable for ongoing management. Options like lamivudine and adefovir are not considered first-line due to higher resistance risk or lower potency, while regimens designed for hepatitis C or HIV therapies aren’t appropriate for hepatitis B.

In chronic hepatitis B, therapy aims to rapidly suppress viral replication with regimens that remain effective over the long term and have low resistance. The best first-line options reflect a balance between immune-modulating therapy and potent antiviral agents. Pegylated interferon provides a finite, immune-based treatment course and can lead to durable responses or even HBsAg loss in some patients, making it an attractive option for those who can tolerate its side effects and who prefer a finite duration of therapy. However, its use is limited by contraindications and tolerability in many patients, such as those with advanced liver disease or autoimmune conditions.

The other two first-line choices are nucleos(t)ide analogues, entecavir and tenofovir. These drugs are highly potent at suppressing HBV DNA, have a high barrier to resistance (especially important for long-term therapy), and are effective in a wide range of patients, including those with cirrhosis. Because they’re taken orally and typically require long-term, potentially lifelong treatment to maintain suppression, their strong resistance profile makes them reliable for ongoing management.

Options like lamivudine and adefovir are not considered first-line due to higher resistance risk or lower potency, while regimens designed for hepatitis C or HIV therapies aren’t appropriate for hepatitis B.